Date: 2018-08-14
Type of information: Nomination
Compound: chief development officer
Company: Allogene Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 14, 2018, Allogene Therapeutics announced the appointment of Susie Jun, M.D., Ph.D., as chief development officer. In her new role at Allogene, she will focus on creating an integrated translational research capability to accelerate clinical development of Allogene’s broad allogeneic CAR T cell portfolio. Dr. Jun has more than 20 years of hematology and oncology clinical research experience across academia and the biopharmaceutical industry. Prior to joining Allogene, she served as Vice President, Head of Development for Abbvie-Stemcentrx Development and also led the Companion Diagnostics Center of Excellence at Abbvie. Dr. Jun has also served as Senior Director, Hem/Onc Clinical Research, at Gilead, and as Executive Medical Director, Hematology/Oncology, at Amgen where she led the development of innovative oncology programs such as Xgeva®, Nplate® and Blincyto®.
- Dr. Jun received her M.D. from the University of Michigan Medical School, and her Ph.D. from The Rockefeller University. She completed her residency in internal medicine at Parkland Memorial Hospital, UT-Southwestern in Dallas, and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center in New York City.
Financial terms:
Latest news:
Is general: Yes
